


B - run

File Copy

RAW SEQUENCE LISTING
ERROR REPORT



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/851,422
Source: 1600
Date Processed by STIC: 7/2/2002

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 3.1 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<http://www.uspto.gov/ebc/efs/downloads/documents.htm>), EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name,
Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
Or
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two,
2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office,
Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002

RECEIVED

JUL 08 2002

TECH CENTER 1600/2900



1600

#12

JN
7/13/02

Does Not Comply
Corrected Diskette Needed

RAW SEQUENCE LISTING
 PATENT APPLICATION: US/09/851,422

DATE: 07/02/2002
 TIME: 14:19:58

Input Set : A:\35879122.app
 Output Set: N:\CRF3\07022002\I851422.raw

3 <110> APPLICANT: YU, XIANXHANG
 4 WAGNER, THOMAS E.
 6 <120> TITLE OF INVENTION: THERAPEUTIC PORE-FORMING PEPTIDES
 8 <130> FILE REFERENCE: 035879/0122
 10 <140> CURRENT APPLICATION NUMBER: 09/851,422
 11 <141> CURRENT FILING DATE: 2001-05-09
 13 <150> PRIOR APPLICATION NUMBER: 60/203,063
 14 <151> PRIOR FILING DATE: 2000-05-09
 16 <150> PRIOR APPLICATION NUMBER: 60/212,042
 17 <151> PRIOR FILING DATE: 2000-06-16
 19 <160> NUMBER OF SEQ ID NOS: 12
 21 <170> SOFTWARE: PatentIn Ver. 2.1
 23 <210> SEQ ID NO: 1
 24 <211> LENGTH: 37
 25 <212> TYPE: PRT
 26 <213> ORGANISM: Artificial Sequence
 28 <220> FEATURE:
 29 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 peptide
 30
 32 <220> FEATURE:
 33 <221> NAME/KEY: MOD_RES
 34 <222> LOCATION: (10)..(13)
 35 <223> OTHER INFORMATION: This region may be selected from the group consisting of
 [epsilon]
 36 -gamma]-Glu, [epsilon-gamma]-Glu-[alpha-gamma]-(Glu)1-3, [epsilon
 37 -alpha]-(Phe)1-3, [epsilon-alpha]-(Tyr)1-3, [epsilon-alpha]
 38 -(Trp)1-3, [epsilon-alpha]-(Lys)1-3 and [epsilon-alpha]-(Arg)1-3.
 40 <220> FEATURE:
 41 <221> NAME/KEY: MOD_RES
 42 <222> LOCATION: (22)..(25)
 43 <223> OTHER INFORMATION: This region may be selected from the group consisting of
 [epsilon]
 44 -gamma]-Glu, [epsilon-gamma]-Glu-[alpha-gamma]-(Glu)1-3, [epsilon
 45 -alpha]-(Phe)1-3, [epsilon-alpha]-(Tyr)1-3, [epsilon-alpha]
 46 -(Trp)1-3, [epsilon-alpha]-(Lys)1-3 and [epsilon-alpha]-(Arg)1-3.
 48 <220> FEATURE:
 49 <221> NAME/KEY: MOD_RES
 50 <222> LOCATION: (34)..(37)
 51 <223> OTHER INFORMATION: This region may be selected from the group consisting of
 [epsilon]
 52 -gamma]-Glu, [epsilon-gamma]-Glu-[alpha-gamma]-(Glu)1-3, [epsilon
 53 -alpha]-(Phe)1-3, [epsilon-alpha]-(Tyr)1-3, [epsilon-alpha]
 54 -(Trp)1-3, [epsilon-alpha]-(Lys)1-3 and [epsilon-alpha]-(Arg)1-3.
 56 <220> FEATURE:

57 <223> OTHER INFORMATION: This molecule may encompass smaller embodiments according
58 to the application as filed

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/851,422

DATE: 07/02/2002
TIME: 14:19:58

Input Set : A:\35879122.app
Output Set: N:\CRF3\07022002\I851422.raw

60 <400> SEQUENCE: 1
W--> 61 Gly Phe Ile Ala Thr Leu Cys Thr Lys Xaa Xaa Xaa Xaa Val Leu Asp
62 1 5 10 15
W--> 64 Phe Gly Ile Asp Lys Xaa Xaa Xaa Xaa Leu Ile Gln Leu Ile Glu Asp
65 20 25 30
W--> 67 Lys Xaa Xaa Xaa Xaa
68 35
71 <210> SEQ ID NO: 2
72 <211> LENGTH: 38
73 <212> TYPE: PRT
74 <213> ORGANISM: Artificial Sequence
76 <220> FEATURE:
77 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
78 peptide
80 <220> FEATURE:
81 <221> NAME/KEY: MOD_RES
82 <222> LOCATION: (8)..(11)
83 <223> OTHER INFORMATION: This region may be selected from the group consisting of
[epsilon]
84 -gamma]-Glu, [epsilon-gamma]-Glu-[alpha-gamma]-(Glu)1-3, [epsilon
85 -alpha]-(Phe)1-3, [epsilon-alpha]-(Tyr)1-3, [epsilon-alpha]
86 -(Trp)1-3, [epsilon-alpha]-(Lys)1-3 and [epsilon-alpha]-(Arg)1-3.
88 <220> FEATURE:
89 <221> NAME/KEY: MOD_RES
90 <222> LOCATION: (26)..(29)
91 <223> OTHER INFORMATION: This region may be selected from the group consisting of
[epsilon]
92 -gamma]-Glu, [epsilon-gamma]-Glu-[alpha-gamma]-(Glu)1-3, [epsilon
93 -alpha]-(Phe)1-3, [epsilon-alpha]-(Tyr)1-3, [epsilon-alpha]
94 -(Trp)1-3, [epsilon-alpha]-(Lys)1-3 and [epsilon-alpha]-(Arg)1-3.
96 <220> FEATURE:
97 <221> NAME/KEY: MOD_RES
98 <222> LOCATION: (32)..(35)
99 <223> OTHER INFORMATION: This region may be selected from the group consisting of
[epsilon]
100 -gamma]-Glu, [epsilon-gamma]-Glu-[alpha-gamma]-(Glu)1-3, [epsilon
101 -alpha]-(Phe)1-3, [epsilon-alpha]-(Tyr)1-3, [epsilon-alpha]
102 -(Trp)1-3, [epsilon-alpha]-(Lys)1-3 and [epsilon-alpha]-(Arg)1-3.
104 <220> FEATURE:
105 <223> OTHER INFORMATION: This molecule may encompass smaller embodiments according
106 to the application as filed
108 <400> SEQUENCE: 2
W--> 109 Gly Ile Gly Ala Val Leu Lys Xaa Xaa Xaa Xaa Val Leu Thr Thr Gly
110 1 5 10 15
W--> 112 Leu Pro Ala Leu Ile Ser Trp Ile Lys Xaa Xaa Xaa Xaa Arg Lys Xaa
113 20 25 30
W--> 115 Xaa Xaa Xaa Arg Gln Gln
116 35
119 <210> SEQ ID NO: 3
120 <211> LENGTH: 25
121 <212> TYPE: PRT
122 <213> ORGANISM: Entamoeba histolytica

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/851,422

DATE: 07/02/2002
TIME: 14:19:58

Input Set : A:\35879122.app
Output Set: N:\CRF3\07022002\I851422.raw

124 <400> SEQUENCE: 3
125 Gly Phe Ile Ala Thr Leu Cys Thr Lys Val Leu Asp Phe Gly Ile Asp
126 1 5 10 15
128 Lys Leu Ile Gln Leu Ile Glu Asp Lys
129 20 25
132 <210> SEQ ID NO: 4
133 <211> LENGTH: 37
134 <212> TYPE: PRT
135 <213> ORGANISM: Antheraea pernyi
137 <220> FEATURE:
138 <223> OTHER INFORMATION: Cecropin A
140 <400> SEQUENCE: 4
141 Lys Trp Lys Leu Phe Lys Lys Ile Glu Lys Val Gly Gln Asn Ile Arg
142 1 5 10 15
144 Asp Gly Ile Ile Lys Ala Gly Pro Ala Val Ala Val Val Gly Gln Ala
145 20 25 30
147 Thr Gln Ile Ala Lys
148 35
151 <210> SEQ ID NO: 5
152 <211> LENGTH: 35
153 <212> TYPE: PRT
154 <213> ORGANISM: Antheraea pernyi
156 <220> FEATURE:
157 <223> OTHER INFORMATION: Cecropin B
160 <400> SEQUENCE: 5
161 Lys Trp Lys Ile Phe Lys Lys Ile Glu Lys Val Gly Arg Asn Ile Arg
162 1 5 10 15
164 Asn Gly Ile Ile Lys Ala Gly Pro Ala Val Ala Val Leu Gly Glu Ala
165 20 25 30
167 Lys Ala Leu
168 35
171 <210> SEQ ID NO: 6
172 <211> LENGTH: 36
173 <212> TYPE: PRT
174 <213> ORGANISM: Antheraea pernyi
176 <220> FEATURE:
177 <223> OTHER INFORMATION: Cecropin D
179 <400> SEQUENCE: 6
180 Trp Asn Pro Phe Lys Glu Leu Glu Lys Val Gly Gln Arg Val Arg Asp
181 1 5 10 15
183 Ala Val Ile Ser Ala Gly Pro Ala Val Ala Thr Val Ala Gln Ala Thr
184 20 25 30
186 Ala Leu Ala Lys
187 35
190 <210> SEQ ID NO: 7
191 <211> LENGTH: 26
192 <212> TYPE: PRT
193 <213> ORGANISM: Apis mellifera
195 <400> SEQUENCE: 7

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/851,422

DATE: 07/02/2002

TIME: 14:19:58

Input Set : A:\35879122.app

Output Set: N:\CRF3\07022002\I851422.raw

196 Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu
 197 1 5 10 15
 199 Ile Ser Trp Ile Lys Arg Lys Arg Gln Gln
 200 20 25
 203 <210> SEQ ID NO: 8
 204 <211> LENGTH: 27
 205 <212> TYPE: PRT
 206 <213> ORGANISM: Artificial Sequence
 208 <220> FEATURE:
 209 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 210 peptide
 212 <220> FEATURE:
 213 <221> NAME/KEY: MOD_RES
 214 <222> LOCATION: (26)..(27)
 215 <223> OTHER INFORMATION: [epsilon-gamma]-Glu-[alpha-gamma]-Glu
 217 <400> SEQUENCE: 8
 218 Gly Phe Ile Ala Thr Leu Cys Thr Lys Val Leu Asp Phe Gly Ile Asp
 219 1 5 10 15
 W-221 Lys Leu Ile Gln Leu Ile Glu Asp Lys Xaa Xaa
 222 20 25
 225 <210> SEQ ID NO: 9
 226 <211> LENGTH: 26
 227 <212> TYPE: PRT
 228 <213> ORGANISM: Artificial Sequence
 230 <220> FEATURE:
 231 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 232 peptide
 234 <220> FEATURE:
 235 <221> NAME/KEY: MOD_RES
 236 <222> LOCATION: (26)
 237 <223> OTHER INFORMATION: [epsilon-alpha]-Phe
 239 <400> SEQUENCE: 9
 240 Gly Phe Ile Ala Thr Leu Cys Thr Lys Val Leu Asp Phe Gly Ile Asp
 241 1 5 10 15
 W-243 Lys Leu Ile Gln Leu Ile Glu Asp Lys Xaa
 244 20 25
 247 <210> SEQ ID NO: 10
 248 <211> LENGTH: 27
 249 <212> TYPE: PRT
 250 <213> ORGANISM: Artificial Sequence
 252 <220> FEATURE:
 253 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 254 peptide
 256 <220> FEATURE:
 257 <221> NAME/KEY: MOD_RES
 258 <222> LOCATION: (18)
 259 <223> OTHER INFORMATION: [epsilon-alpha]-Phe
 261 <220> FEATURE:
 262 <221> NAME/KEY: MOD_RES

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/851,422

DATE: 07/02/2002
TIME: 14:19:58

Input Set : A:\35879122.app
Output Set: N:\CRF3\07022002\I851422.raw

263 <222> LOCATION: (27)
 264 <223> OTHER INFORMATION: [epsilon-alpha]-Phe
 266 <400> SEQUENCE: 10
 267 Gly Phe Ile Ala Thr Leu Cys Thr Lys Val Leu Asp Phe Gly Ile Asp
 268 1 5 10 15
 w--> 270 Lys Xaa Leu Ile Gln Leu Ile Glu Asp Lys Xaa
 271 20 25
 274 <210> SEQ ID NO: 11
 275 <211> LENGTH: 28
 276 <212> TYPE: PRT
 277 <213> ORGANISM: Artificial Sequence
 279 <220> FEATURE:
 280 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 281 peptide
 283 <220> FEATURE:
 284 <221> NAME/KEY: MOD_RES
 285 <222> LOCATION: (22)
 286 <223> OTHER INFORMATION: [epsilon-gamma]-Glu
 288 <220> FEATURE:
 289 <221> NAME/KEY: MOD_RES
 290 <222> LOCATION: (25)
 291 <223> OTHER INFORMATION: [epsilon-gamma]-Glu
 293 <400> SEQUENCE: 11
 294 Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu
 295 1 5 10 15
 Ok--> 297 Ile Ser Trp Ile Lys Xaa Arg Lys Xaa Arg Gln Gln
 298 20 25
 301 <210> SEQ ID NO: 12
 302 <211> LENGTH: 30
 303 <212> TYPE: PRT
 304 <213> ORGANISM: Artificial Sequence
 306 <220> FEATURE:
 307 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 308 peptide
 310 <220> FEATURE:
 311 <221> NAME/KEY: MQD_RES
 312 <222> LOCATION: (19)..(20) "Trp" is at location 19 and "Ile" is at
 313 <223> OTHER INFORMATION: [epsilon-gamma]-Glu-[alpha-gamma]-Glu location 20
 315 <220> FEATURE:
 316 <221> NAME/KEY: MOD_RES
 317 <222> LOCATION: (23)..(24) what about Xaa at location 22?
 318 <223> OTHER INFORMATION: [epsilon-gamma]-Glu-[alpha-gamma]-Glu "Arg" is at location 24
 320 <400> SEQUENCE: 12
 321 Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu
 322 1 5 10 15
 W--> 324 Ile Ser Trp Ile Lys Xaa Xaa Arg Lys Xaa Xaa Arg Gln Gln
 325 20 25 30
 what about Xaa's at locations 26 and 27?

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/09/851,422

DATE: 07/02/2002
TIME: 14:19:59

Input Set : A:\35879122.app
Output Set: N:\CRF3\07022002\I851422.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:1; Xaa Pos. 10,11,12,13,22,23,24,25,34,35,36,37
Seq#:2; Xaa Pos. 8,9,10,11,26,27,28,29,32,33,34,35
Seq#:8; Xaa Pos. 26,27
Seq#:9; Xaa Pos. 26
Seq#:10; Xaa Pos. 18,27
Seq#:11; Xaa Pos. 22,25
Seq#:12; Xaa Pos. 22,23,26,27